Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000CHP2222
Thu, 01.12.2022
Cheplapharm AG
Patrick König leaves CHEPLAPHARM at his own request
Klaus Köhl becomes new Chief Operating Officer
Patrick König leaves the Company at the end of the year at his own request.
Patrick König has worked for CHEPLAPHARM for a total of almost five years. In 2018, the business graduate started at the pharmaceutical company specializing in well-esta [ … ]
Tue, 29.11.2022
Cheplapharm AG
Double-digit revenue and earnings growth after nine months in 2022
Transformation program launched to optimize organization
Significant annual revenue growth planned until 2025
CHEPLAPHARM AG, a leading international platform for well-established branded medicines, remains on growth track. After achieving the highest revenue in the Company's h [ … ]
Tue, 29.11.2022
Cheplapharm AG
Double-digit revenue and earnings growth after nine months in 2022
Transformation program launched to optimize organization
Significant annual revenue growth planned until 2025
CHEPLAPHARM AG, a leading international platform for well-established branded medicines, remains on growth track. After achieving the highest revenue in the Company's h [ … ]
Tue, 25.10.2022
Cheplapharm AG
Atlantic Park and GIC will invest a total of €550m in CHEPLAPHARM.
The transaction will strengthen and diversify CHEPLAPHARM’s financial base and help fuel the Company’s growth.
Greifswald, 25 October 2022 -CHEPLAPHARM AG, a leading international platform for well-established branded medicines, today announced that it has entered into a definiti [ … ]
Tue, 25.10.2022
Cheplapharm AG
Atlantic Park and GIC will invest a total of €550m in CHEPLAPHARM.
The transaction will strengthen and diversify CHEPLAPHARM’s financial base and help fuel the Company’s growth.
Greifswald, 25 October 2022 -CHEPLAPHARM AG, a leading international platform for well-established branded medicines, today announced that it has entered into a definiti [ … ]
Mon, 29.08.2022
Cheplapharm AG
CHEPLAPHARM INCREASES REVENUE AND EARNINGS IN THE FIRST HALF OF 2022
Revenue increases by 20% to €594m in the first half of the year
EBITDA grows by 4% to €343m
EBITDA margin at 58%
Greifswald, 29 August 2022 - CHEPLAPHARM AG, a leading international platform for well-established branded medicines, is continuing its growth path. After achiev [ … ]
Mon, 29.08.2022
Cheplapharm AG
CHEPLAPHARM INCREASES REVENUE AND EARNINGS IN THE FIRST HALF OF 2022
Revenue increases by 20% to €594m in the first half of the year
EBITDA grows by 4% to €343m
EBITDA margin at 58%
Greifswald, 29 August 2022 - CHEPLAPHARM AG, a leading international platform for well-established branded medicines, is continuing its growth path. After achiev [ … ]
Fri, 29.04.2022
Cheplapharm AG
- Revenue exceeds €1bn for the first time: +69% YOY to €1,082.0m (FY2020: €639.6m)
- EBITDA +86% YOY to €623.9m (FY2020: €335.1m)
- Further increased EBITDA margin (58% vs. 52% in FY2020) and gross profit margin (75% vs. 70% in FY2020) demonstrating continued operational leverage with scale
- Free cash flow grew by +41% to €371.3m (FY2020: €264. [ … ]
Wed, 23.02.2022
Cheplapharm AG
JENS ROTHSTEIN HANDS OVER HIS CFO ROLE TO KIA PARSSANEDJAD
Greifswald, 23 February 2022 -
Cheplapharm AG ("Cheplapharm" or "the Company"), a specialty pharmaceutical company which is a global leader in investing in long established and trusted pharma brands and enhancing them with life-cycle-management, today announced a change in senior leadership [ … ]
Fri, 11.02.2022
Cheplapharm AG
CHEPLAPHARM GMBH ANNOUNCES SUCCESSFUL PRICING OF TERM LOAN B
Greifswald, 11 February 2022
Cheplapharm is proud to announce today that it has signed a new term loan facility of €1,480 million. The proceeds from the new term loan facility will be used to roll the Company's existing €980 million term loan facility in full and for general corporate pu [ … ]